Depression is a common disorder with an annual risk of a depressive episode in the United States of 6.6%. Only 30-40% of patients remit with antidepressant monotherapy, leaving 60-70% of patients who do not optimally respond to therapy. Unremitted depressive patients are at increased risk for suicide. Considering the prevalence of treatment resistant depression and its consequences, treatment optimization is imperative. This review summarizes the latest treatment modalities for major depressive disorder including pharmacotherapy, electroconvulsive therapy, repetitive transcranial magnetic stimulation and psychotherapy. Through advancements in research to better understand the pathophysiology of depression, advances in treatment will be realized.
CITATION STYLE
Block, S. G., & Nemeroff, C. B. (2014). Emerging antidepressants to treat major depressive disorder. Asian Journal of Psychiatry. Elsevier. https://doi.org/10.1016/j.ajp.2014.09.001
Mendeley helps you to discover research relevant for your work.